Celularity Inc.(CELU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CELU Celularity Inc.

Closed 12-22 16:00:00 EST

1.32

-0.13

-8.97%

盘后1.32

+0.000.00%

19:31 EST

High1.48	Low1.27	Vol126.71K
Open1.45	D1 Closing1.45	Amplitude14.48%
Mkt Cap37.39M	Tradable Cap21.28M	Total Shares28.33M
T/O174.37K	T/O Rate0.79%	Tradable Shares16.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CELU","market":"US","secType":"STK","nameCN":"Celularity Inc.","latestPrice":1.32,"timestamp":1766437200000,"preClose":1.45,"halted":0,"volume":126707,"hourTrading":{"tag":"盘后","latestPrice":1.32,"preClose":1.32,"latestTime":"19:31 EST","volume":106,"amount":140.02,"timestamp":1766449875334},"delay":0,"floatShares":16123000,"shares":28328880,"eps":-3.209195,"marketStatus":"Closed","change":-0.13,"latestTime":"12-22 16:00:00 EST","open":1.45,"high":1.48,"low":1.27,"amount":174369.7893378,"amplitude":0.144828,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.209195,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.45,"preHourTrading":{"tag":"盘前","latestPrice":1.45,"preClose":1.45,"latestTime":"07:53 EST","volume":105,"amount":152.25,"timestamp":1766408009695},"postHourTrading":{"tag":"盘后","latestPrice":1.32,"preClose":1.32,"latestTime":"19:31 EST","volume":106,"amount":140.02,"timestamp":1766449875334},"volumeRatio":1.456058,"impliedVol":1.2271,"impliedVolPercentile":0.632},"requestUrl":"/m/hq/s/CELU","defaultTab":"news","newsList":[{"id":"2593583164","title":"Press Release: Celularity Announces Closing of Financing Transactions","url":"https://stock-news.laohu8.com/highlight/detail?id=2593583164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593583164?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:01","pubTimestamp":1766437260,"startTime":"0","endTime":"0","summary":"FLORHAM PARK, N.J., Dec. 22, 2025  -- Celularity Inc.  , a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.At the closing, Celularity received $10.00 million in gross proceeds. The transaction structure provides for the potential availability of up to an additional $2.0 million, subject to the satisfaction of specified closing conditions and the investor's election, as set forth in the definitive agreements. The financing includes a senior secured term loan and a secured convertible note, and is intended to support Celularity's ongoing operations and strategic initiatives.The securities described above were sold in a private placemen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELU"],"gpt_icon":0},{"id":"2592819708","title":"Celularity Inc. held annual stockholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592819708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592819708?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:16","pubTimestamp":1766178977,"startTime":"0","endTime":"0","summary":"Celularity Inc. held its Annual Meeting of Stockholders on December 19, 2025. Stockholders elected Peter Diamandis, M.D., Diane Parks, and Geoffrey Ling, M.D. to the Board of Directors. Stockholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. An amendment to increase the number of shares available under the 2021 Equity Incentive Plan was not approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL5BHdFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELU","BK4139"],"gpt_icon":0},{"id":"2592186706","title":"Celularity Secures Up to $12M in Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2592186706","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592186706?lang=en_us&edition=fundamental","pubTime":"2025-12-19 03:33","pubTimestamp":1766086380,"startTime":"0","endTime":"0","summary":"Celularity entered into two binding term sheets for a senior secured term loan and a secured convertible note, adding up to $12 million in new financing.The cellular medicine company said Thursday it expects initial proceeds of $10 million with the availability of additional funding up to $2 million subject to certain conditions.The funding is from Philip Barach, the co-founder and former president of DoubleLine Capital, a Los Angeles investment-management firm.The senior secured term loan has a stated principal amount of $7 million.The convertible notes provide for aggregate commitments of up to $5 million, issuable in multiple tranches. They are convertible into shares of Celularity's Class A stock at a conversion price of $1.66 a share.In connection with the transactions, Celularity has agreed to issue warrants to purchase shares of its Class A common stock equal to 33% of the as-converted principal amount. The warrants will become exercisable six months after the issuance and have ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELU"],"gpt_icon":0},{"id":"2592186118","title":"Celularity Inc - to Receive up to $12 Mln in Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592186118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592186118?lang=en_us&edition=fundamental","pubTime":"2025-12-19 03:10","pubTimestamp":1766085000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA1X98YC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CELU","BK4139"],"gpt_icon":0},{"id":"2592318614","title":"Press Release: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision","url":"https://stock-news.laohu8.com/highlight/detail?id=2592318614","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592318614?lang=en_us&edition=fundamental","pubTime":"2025-12-19 03:10","pubTimestamp":1766085000,"startTime":"0","endTime":"0","summary":"-- The contemplated financing transactions would provide up to $12 Million. in capital to support Celularity's strategic priorities around longevity. FLORHAM PARK, N.J., Dec. 18, 2025  -- Celularity Inc.  , a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of DoubleLine Capital LP, a Los Angeles-based investment management firm. The contemplated financing transactions are contingent upon the parties executing formal transaction agreements, which the parties expect to do shortly.Under the terms of the binding term sheets, Celularity expects to receive initial proceeds of $10.0 million, with the availability of additional funding of up to $2.0 million subject to certain conditions and the investor's election, as will be set forth in the definitive agreeme","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELU","BK4139"],"gpt_icon":0},{"id":"2591625015","title":"There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625015","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591625015?lang=en_us&edition=fundamental","pubTime":"2025-12-16 01:04","pubTimestamp":1765818276,"startTime":"0","endTime":"0","summary":"With a price-to-sales (or \"P/S\") ratio of 1.1x Celularity Inc. ( NASDAQ:CELU ) may be sending very bullish signals at...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celu/celularity/news/there-is-a-reason-celularity-incs-nasdaqcelu-price-is-undema","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celu/celularity/news/there-is-a-reason-celularity-incs-nasdaqcelu-price-is-undema","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","USAW.SI",".IXIC","SQQQ","NQmain","USJW.SI","MNQmain","BK4139","PSQ","TQQQ","QID","TSYW.SI","CELU","NVIW.SI"],"gpt_icon":1},{"id":"2589981099","title":"Celularity Inc - FDA Requires Limiting Outcome-Based Claims for Interfyl - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589981099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589981099?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:34","pubTimestamp":1764970477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0Y6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CELU","BK4139"],"gpt_icon":0},{"id":"2589810994","title":"Celularity Inc - Receives FDA Warning Letter on Marketing Material - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589810994","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589810994?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:34","pubTimestamp":1764970477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0Y6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CELU"],"gpt_icon":0},{"id":"2589810605","title":"FDA Warns Celularity Over Marketing Claims for Interfyl","url":"https://stock-news.laohu8.com/highlight/detail?id=2589810605","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589810605?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:31","pubTimestamp":1764970291,"startTime":"0","endTime":"0","summary":"Celularity Inc. has received a warning letter from the U.S. Food and Drug Administration  regarding its marketing practices for Interfyl, a human connective tissue matrix product. The FDA's letter instructs the company to limit the use of outcome-based claims and assertions about metabolic activity in its promotional materials to comply with regulations under Section 361 of CFR 1271.10. While the letter does not restrict manufacturing or shipping operations, nor require a product recall, Celularity faces potential further regulatory action if the FDA's concerns are not resolved. The company states it is working with the FDA to address the issues and does not expect an immediate material impact on its operations or financial outlook.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interprete","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL4l7GJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELU"],"gpt_icon":0},{"id":"2581833662","title":"Celularity Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581833662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581833662?lang=en_us&edition=fundamental","pubTime":"2025-11-08 02:14","pubTimestamp":1762539293,"startTime":"0","endTime":"0","summary":"Celularity Inc. has announced its 2026 Annual Meeting of Stockholders, with stockholders of record at the close of business on October 30, 2025, entitled to vote at the meeting. During the meeting, stockholders will vote on the election of director nominees and the approval of other proposals outlined for consideration. Additionally, the meeting will address any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. The meeting will be held at the company's headquarters in Florham Park, New Jersey.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL1v4DT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELU","BK4139"],"gpt_icon":0},{"id":"2578968540","title":"BRIEF-Celularity - Enters Securities Purchase Agreement For Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2578968540","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578968540?lang=en_us&edition=fundamental","pubTime":"2025-10-28 21:56","pubTimestamp":1761659772,"startTime":"0","endTime":"0","summary":"BRIEF-Celularity - Enters Securities Purchase Agreement For Private PlacementOct 28 (Reuters) - Celularity Inc CELU.O:CELULARITY INC - ENTERS SECURITIES PURCHASE AGREEMENT FOR PRIVATE PLACEMENT - SEC FILINGFurther company coverage: CELU.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nFWN3W90WI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELU"],"gpt_icon":0},{"id":"2578957011","title":"Celularity Inc - Enters Securities Purchase Agreement for Private Placement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2578957011","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578957011?lang=en_us&edition=fundamental","pubTime":"2025-10-28 21:31","pubTimestamp":1761658268,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nFWN3W90WI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CELU","BK4139"],"gpt_icon":0},{"id":"2578957005","title":"Celularity Inc. Sells Series A Preferred Stock and Warrants in $2 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2578957005","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578957005?lang=en_us&edition=fundamental","pubTime":"2025-10-28 21:30","pubTimestamp":1761658219,"startTime":"0","endTime":"0","summary":"Celularity Inc. has entered into a Securities Purchase Agreement with an institutional investor to issue and sell Series A Convertible Preferred Stock and accompanying warrants in a private placement of up to three tranches. Each tranche involves $2,000,000 in gross proceeds , for a total aggregate stated value of up to $6,666,667. The Series A Preferred Stock will be sold at 90% of the stated value, with a conversion floor price of $1.60 per share, subject to adjustments. The initial tranche closed on October 24, 2025, with additional tranches subject to certain conditions and at the investor's option. The company intends to use the net proceeds for working capital and general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL12S1Gq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELU"],"gpt_icon":0},{"id":"2575182492","title":"Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (Pda-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2575182492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575182492?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:45","pubTimestamp":1760445900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUABYVJBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CELUW","BK4139","CELU"],"gpt_icon":0},{"id":"2566619864","title":"Celularity Raised to Buy From Hold by WBB Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2566619864","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566619864?lang=en_us&edition=fundamental","pubTime":"2025-09-09 23:25","pubTimestamp":1757431500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CELU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 09, 2025 11:25 ET (15:25 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELU"],"gpt_icon":0},{"id":"2563072475","title":"Celularity Inc. Reports No Revenue from Cellular Therapies, Continues to Operate at a Loss in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2563072475","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563072475?lang=en_us&edition=fundamental","pubTime":"2025-08-30 05:19","pubTimestamp":1756502342,"startTime":"0","endTime":"0","summary":"Celularity Inc., a clinical-stage biotechnology company, released its financial results for the quarter ending March 31, 2025. The company reported its financial performance with a focus on its three business segments: Cell Therapy, Degenerative Disease, and BioBanking. The report highlights that Celularity has not generated revenue from the sale of cellular therapies, as it continues to invest substantially in research and development activities, including pre-clinical studies and clinical development of cell programs. These investments have been funded through limited revenues and have impacted the company's short-term profitability. The company continues to operate as a going concern, relying on its ability to realize assets and settle liabilities in the normal course of business. Celularity's management is focused on advancing its cellular therapy programs, which remain unproven and in various phases of development. The company's outlook emphasizes the inherent risks and uncertaint","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL5rqL69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELU"],"gpt_icon":0},{"id":"2561285714","title":"BRIEF-Celularity Receives Nasdaq Notice Regarding Form 10-Q","url":"https://stock-news.laohu8.com/highlight/detail?id=2561285714","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561285714?lang=en_us&edition=fundamental","pubTime":"2025-08-23 06:31","pubTimestamp":1755901892,"startTime":"0","endTime":"0","summary":"BRIEF-Celularity Receives Nasdaq Notice Regarding Form 10-QCelularity Inc CELU.O:CELULARITY RECEIVES NASDAQ NOTICE REGARDING FORM 10-QSource text: ID:nGNXbyxTnwFurther company coverage: CELU.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nTUA16RLXS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELUW","BK4139","CELU"],"gpt_icon":0},{"id":"2560790181","title":"Celularity Initiated at Speculative Buy by WBB Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2560790181","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560790181?lang=en_us&edition=fundamental","pubTime":"2025-08-19 00:06","pubTimestamp":1755533160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CELU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 12:06 ET (16:06 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELU"],"gpt_icon":0},{"id":"2560857851","title":"BRIEF-Celularity Completes Major Balance Sheet Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2560857851","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560857851?lang=en_us&edition=fundamental","pubTime":"2025-08-18 22:16","pubTimestamp":1755526578,"startTime":"0","endTime":"0","summary":"BRIEF-Celularity Completes Major Balance Sheet RestructuringAug 18 (Reuters) - Celularity Inc CELU.O:CELULARITY COMPLETES MAJOR BALANCE SHEET RESTRUCTURING, RETIRES ALL $41.6 MILLION IN SENIOR SECURED","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nTUA9YR1N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELUW","CELU"],"gpt_icon":0},{"id":"2560024469","title":"Celularity Inc: Sold Its Intellectual Property Assets to Celeniv for $33.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2560024469","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560024469?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:00","pubTimestamp":1755518400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nTUA9YR1N4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CELU"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celularity.com","stockEarnings":[{"period":"1week","weight":-0.0938},{"period":"1month","weight":-0.142},{"period":"3month","weight":-0.3468},{"period":"6month","weight":-0.1761},{"period":"1year","weight":-0.3483},{"period":"ytd","weight":-0.3029}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products. The company was founded in 1998 and is based in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.001846},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.014952},{"month":3,"riseRate":0.5,"avgChangeRate":0.173641},{"month":4,"riseRate":0.5,"avgChangeRate":-0.041609},{"month":5,"riseRate":0.666667,"avgChangeRate":0.086371},{"month":6,"riseRate":0.5,"avgChangeRate":-0.159828},{"month":7,"riseRate":0.333333,"avgChangeRate":0.031304},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.023952},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.157824},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.097694},{"month":11,"riseRate":0.571429,"avgChangeRate":0.028019},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.069831}],"exchange":"NASDAQ","name":"Celularity Inc.","nameEN":"Celularity Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celularity Inc.(CELU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Celularity Inc.(CELU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Celularity Inc.,CELU,Celularity Inc.股票,Celularity Inc.股票老虎,Celularity Inc.股票老虎国际,Celularity Inc.行情,Celularity Inc.股票行情,Celularity Inc.股价,Celularity Inc.股市,Celularity Inc.股票价格,Celularity Inc.股票交易,Celularity Inc.股票购买,Celularity Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celularity Inc.(CELU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Celularity Inc.(CELU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction